High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis

• Published in: The Journal of clinical investigation Vol. 132; no. 6
• Main Authors: Ruiz-Bedoya, Camilo A, Mota, Filipa, Tucker, Elizabeth W, Mahmud, Farina J, Reyes-Mantilla, Maria I, Erice, Clara, Bahr, Melissa, Flavahan, Kelly, de Jesus, Patricia, Kim, John, Foss, Catherine A, Peloquin, Charles A, Hammoud, Dima A, Ordonez, Alvaro A, Pardo, Carlos A, Jain, Sanjay K
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 15-03-2022
• Subjects: Animals; Antitubercular Agents; Dosage and administration; Drug therapy; Humans; Infectious disease; Inflammation - complications; Inflammation - drug therapy; Mice; Microbiology; Models, Animal; Rabbits; Rifampin; Rifampin - therapeutic use; Testing; Tuberculosis, Meningeal - complications; Tuberculosis, Meningeal - drug therapy; Tuberculous meningitis; United States; Neuroimaging; Infectious disease; Pharmacology; Microbiology; Neurological disorders
• ISSN: 1558-8238; 0021-9738; 1558-8238
• DOI: 10.1172/JCI155851

Tuberculous meningitis (TB meningitis) is the most severe form of tuberculosis (TB), requiring 12 months of multidrug treatment for cure, and is associated with high morbidity and mortality. High-dose rifampin (35 mg/kg/d) is safe and improves the bactericidal activity of the standard-dose (10 mg/kg/d) rifampin-containing TB regimen in pulmonary TB. However, there are conflicting clinical data regarding its benefit for TB meningitis, where outcomes may also be associated with intracerebral inflammation. We conducted cross-species studies in mice and rabbits, demonstrating that an intensified high-dose rifampin-containing regimen has significantly improved bactericidal activity for TB meningitis over the first-line, standard-dose rifampin regimen, without an increase in intracerebral inflammation. Positron emission tomography in live animals demonstrated spatially compartmentalized, lesion-specific pathology, with postmortem analyses showing discordant brain tissue and cerebrospinal fluid rifampin levels and inflammatory markers. Longitudinal multimodal imaging in the same cohort of animals during TB treatment as well as imaging studies in two cohorts of TB patients demonstrated that spatiotemporal changes in localized blood-brain barrier disruption in TB meningitis are an important driver of rifampin brain exposure. These data provide unique insights into the mechanisms underlying high-dose rifampin in TB meningitis with important implications for developing new antibiotic treatments for infections.